Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.37 |
| ▸ | FDPS | P14324 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10629979 | 0.92 | BLM (0.44) | BLMLMNACNR1TP53SMN1; SMN2 | |
| SCHEMBL10605262 | 0.85 | BLM (0.49) | BLMLMNACNR1TP53SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL10603462 | 0.83 | BLM (0.47) | BLMLMNACNR1TP53SMN1; SMN2 | |
| SCHEMBL14414107 | 0.82 | CASP2 (0.50) | BLMCNR1 | |
| SCHEMBL14273835 | 0.82 | CASP2 (0.50) | BLMCNR1 | |
| SCHEMBL10634457 | 0.82 | DNM1 (0.44) | BLMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL4716888 | 0.82 | CASP2 (0.50) | BLMCNR1 | |
| Hydrochloric Acid SCHEMBL10630004 | 0.81 | DNM1 (0.43) | BLMLMNATP53SMN1; SMN2KMT2A | |
| SCHEMBL5165428 | 0.81 | BLM (0.47) | BLMLMNACNR1CNR2KMT2A | |
| SCHEMBL10634701 | 0.80 | BLM (0.40) | BLMLMNATP53SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | MELBOURNE INST TECH (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4531812-A1 | LIPID NANOCARRIER VACCINE | Royal Melbourne Institute of Technology (AU) | 2025-04-09 | — | — | EP | claimed |
| US-20230404921-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-12-21 | — | — | US | claimed |
| WO-2023225722-A1 | LIPID NANOCARRIER VACCINE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-11-30 | — | — | WO | claimed |
| EP-4236916-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | Royal Melbourne Institute of Technology (AU) | 2023-09-06 | — | — | EP | claimed |
| WO-2022087686-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2022-05-05 | — | — | WO | claimed |
| WO-2010139003-A1 | CHELATING AMPHIPHILES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-12-09 | — | — | WO | claimed |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | MELBOURNE INST TECH (AU) | 2025-11-06 | — | — | US | disclosed |
| US-20250281406-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2025-09-11 | — | — | US | disclosed |
| EP-4531812-A1 | LIPID NANOCARRIER VACCINE | Royal Melbourne Institute of Technology (AU) | 2025-04-09 | — | — | EP | disclosed |
| EP-4511065-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | Royal Melbourne Institute of Technology (AU) | 2025-02-26 | — | — | EP | disclosed |
| US-20230404921-A1 | LYOTROPIC LIQUID CRYSTALLINE PHASE PARTICLE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-12-21 | — | — | US | disclosed |
| WO-2023225722-A1 | LIPID NANOCARRIER VACCINE | ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY (AU) | 2023-11-30 | — | — | WO | disclosed |
| WO-2010139003-A1 | CHELATING AMPHIPHILES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2010-12-09 | — | — | WO | disclosed |
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | DSM ASSETS B.V. (NL) | 2009-10-15 | — | — | US | disclosed |
| EP-1926703-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP Assets B.V. (NL) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007039059-A1 | NOVEL CARBOXYLIC ACID DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2007-04-12 | — | — | WO | disclosed |
| US-4762829-A | ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1988-08-09 | — | — | US | disclosed |
| US-4742058-A | AMIDES, ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
| EP-0110397-A2 | Polyprenyl compound and drug containing the same | Eisai Co., Ltd. (JP) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281406-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR DELIVERY OF BIOLOGICALLY ACTIVE AGENTS | LIPA, LIPG, SGMS1 | BLM 281/4885LMNA 393/4885CNR1 1933/4885 |
| US-20090258887-A1 | Novel Carboxylic Acid Derivatives | AADAC, ALDH7A1, DDC | BLM 4731/4885LMNA 3280/4885CNR1 583/4885 |
| US-20250339517-A1 | LIPID NANOCARRIER VACCINE | CD47, LY96, TSG101 | BLM 1467/4885LMNA 2681/4885CNR1 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.